Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?

ESMO Open. 2024 May;9(5):102983. doi: 10.1016/j.esmoop.2024.102983. Epub 2024 Apr 24.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols* / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Bevacizumab* / pharmacology
  • Bevacizumab* / therapeutic use
  • Female
  • Humans
  • Maintenance Chemotherapy / methods
  • Mutation
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use

Substances

  • Bevacizumab
  • Poly(ADP-ribose) Polymerase Inhibitors
  • BRCA1 Protein
  • BRCA2 Protein